Corvus Pharmaceuticals (CRVS) Long-Term Deferred Tax (2016 - 2019)

Corvus Pharmaceuticals' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $54.9 million for Q4 2019.

• On a quarterly basis, Long-Term Deferred Tax rose 74.02% year-over-year to $54.9 million in Q4 2019; TTM through Dec 2019 was $54.9 million, a 74.02% increase from a year earlier, with the FY2019 full-year figure at $54.9 million, up 74.02% from the prior year.
• Long-Term Deferred Tax grew to $54.9 million in Q4 2019 per CRVS's latest filing, from $31.5 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $54.9 million in Q4 2019 and bottomed at $9.3 million in Q4 2016.
• The 4-year median for Long-Term Deferred Tax is $23.5 million (2017), against an average of $27.8 million.
• Across the five-year window, Long-Term Deferred Tax jumped 65.31% in 2017 and jumped 104.26% in 2018, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $9.3 million in 2016, then surged by 65.31% to $15.4 million in 2017, then surged by 104.26% to $31.5 million in 2018, then surged by 74.02% to $54.9 million in 2019.
• Per Business Quant, the three latest CRVS Long-Term Deferred Tax figures stand at $54.9 million (Q4 2019), $31.5 million (Q4 2018), and $15.4 million (Q4 2017).